ELI LILLY & Co
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1410.99−6.55 (-0.46%)
Close on Nov 2, 2026Market cap $1.33TP/E 45.8Yield 0.44%
Eli Lilly Non-GAAP diluted earnings per share by Quarter
Non-GAAP diluted earnings per share ($) ($)
Eli Lilly Non-GAAP diluted earnings per share: $8.38 in Q2 2026, up 32.8% from a year earlier.
Latest, Q2 2026
8.38
Period ended Jun 30, 2026
Change on a year earlier
+32.8%
6.31 in Q2 2025
History
37 quarters
Since Q4 2016
Sources
30
Documents cited below
Where the Q2 2026 figure comes from
“|| Earnings per share (diluted) - Non-GAAP | $ | 8.38 | $ | 6.31 | $ | 16.94 | $ | 9.65 1.Excludes amortization of intangibles primarily associated with costs of marketed products acquired or licensed from third parties. 2.For the three months ended June 30, 2026, excluded charges primarily related to the accelerated vesting of employee equity awards and other acquisition and integration costs associated with the closing of the company's acquisitions of Kelonia Therapeutics, Inc. and Centessa Pharmaceuticals plc. For the six months ended June 30, 2026, also excluded charges related to litigation matters.”
Source: Earnings Release (Form 8-K FY2026Q2 EX-99.1) (filed 2026-08-05) ↗
Reported in Form 8-K Non-GAAP Reconciliation Schedules.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Eli Lilly Non-GAAP diluted earnings per share ($), quarterly Q4 2016–Q2 2026 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/eps-nongaap
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.